查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1744575

2032 年心房顫動市場預測：按產品類型、療法、技術、最終用戶和地區進行的全球分析

Atrial Fibrillation Market Forecasts to 2032 - Global Analysis By Product (Surgical Devices, Non-Surgical Devices and Pharmacological Drugs), Type, Treatment, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球心房顫動市場預計在 2025 年達到 176 億美元，到 2032 年將達到 273 億美元，預測期內的複合年成長率為 6.5%。

心房顫動是一種心律不整，其特徵是心房（心臟上腔）快速且不規則地跳動。當心房內的電訊號變得混亂並擾亂正常心律時，就會發生心房顫動。這會導致血液循環不良，並增加中風、心臟衰竭和其他心臟相關併發症的風險。常見症狀包括心悸、疲勞、胸部不適和呼吸急促。早期診斷和藥物治療、生活方式改變和手術干預對於有效治療至關重要。

根據美國國家生物技術資訊中心2021年發表的論文，估計全球心房顫動的患病人數約為3,750萬人，預計到2050年將增加60.0%以上。

全球心血管疾病盛行率不斷上升

心房顫動 (AFib) 盛行率的上升與人口老化和生活方式相關的風險因素有關。肥胖、高血壓和糖尿病是心血管疾病負擔加重的主要原因。對心房顫動症狀的認知不斷提高，促使人們能夠更早進行診斷和治療。久坐的生活方式和壓力相關疾病進一步增加了心臟病的風險。診斷工具的進步使得人們能夠更好地檢測心房顫動病例。全球對有效心房顫動治療的需求日益成長。

心房顫動治療相關的風險和併發症

心導管電氣燒灼術等心房顫動治療有出血及感染風險。抗凝血劑會增加過度出血等副作用的風險。先進療法費用高昂，許多患者難以負擔。複雜的手術需要熟練的專業人員，而這類專業人員卻十分稀缺。患者不堅持長期藥物治療也是另一個挑戰。這些因素阻礙了心房顫動治療的廣泛應用。

微創治療方法的發展

心導管電氣燒灼術等微創治療方法因其恢復時間更短而日益受到青睞。消融技術的創新提高了準確性和患者預後。不斷成長的研究投入支持了更安全治療方法的開發。用於即時心臟監測的穿戴式設備增強了早期療育策略。醫療設備公司和醫療保健提供者之間的合作推動了創新。這些進步為心房顫動市場創造了巨大的成長機會。

醫療設備製造商之間的激烈競爭

心房顫動治療市場面臨各大醫療設備公司之間的激烈競爭。快速的技術進步迫使製造商不斷創新。規模較小的企業難以與提供先進解決方案的知名品牌競爭。價格戰和成本削減策略影響利潤率。新設備核准的監管障礙阻礙了新設備的市場進入。激烈的競爭可能導致市場飽和，從而限制新參與企業的成長。

COVID-19的影響：

由於醫院資源緊張，COVID-19疫情導致選擇性心房顫動治療中斷。遠端醫療的應用激增，使得對心房顫動患者進行遠端監控成為可能。供應鏈問題影響了關鍵醫療設備的供應。疫情凸顯了高風險患者早期發現心房顫動的重要性。後疫情時代，醫療支出的增加加速了市場復甦。人們對心臟健康的認知不斷提高，持續推動對心房顫動治療的需求。

陣發性心房顫動細分市場預計將成為預測期內最大的細分市場

由於陣發性心房顫動在確診病例中盛行率較高，預計該領域將在預測期內佔據最大的市場佔有率。其間歇性特徵推動了對早期診斷和治療方案的需求。穿戴式監測設備的進步有助於及時發現陣發性心房顫動。患者對微創治療的偏好推動了該領域的成長。醫療保健可近性的提高有助於對陣發性心房顫動進行早期療育。該領域正受益於標靶治療的持續研究。

預計醫療治療領域在預測期內將實現最高的複合年成長率。

預計藥物治療領域將在預測期內達到最高成長率。抗凝血劑和抗心律不整藥物在控制心房顫動症狀方面仍然至關重要。對新型藥物製劑的持續研究正在提高治療效果。患者對非侵入性治療的偏好推動了對藥物解決方案的需求。新興市場醫療保健可近性的提高也支持了該領域的成長。個人化醫療的創新將進一步加速藥物治療的普及。

佔比最大的地區：

在預測期內，亞太地區預計將佔據最大的市場佔有率，這得益於其龐大的老齡化人口和不斷成長的房顫患者數量。中國和印度等國家醫療支出的增加正在推動市場成長。該地區不斷擴大的醫療基礎設施為先進的房顫治療提供支援。人們對心血管健康的認知不斷提高，刺激了對診斷工具的需求。政府為改善醫療保健可近性而採取的措施增強了市場潛力。大型醫療設備製造商的存在增強了該地區的主導地位。

複合年成長率最高的地區：

在預測期內，北美預計將憑藉其先進的醫療體系實現最高的複合年成長率。心導管電氣燒灼術等創新型心房顫動治療手段的廣泛採用正在推動市場擴張。該地區高度重視研發，推動技術進步。生活方式相關風​​險因素的日益增加導致心房顫動患者數量增加。支持性報銷政策增加了患者獲得治療的機會。主要企業之間的策略夥伴關係將進一步推動市場成長。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球心房顫動市場（按產品）

  • 手術設備
  • 非手術器械
  • 藥理藥物

6. 全球心房顫動市場（按類型）

  • 陣發性心房顫動
  • 持續性心房顫動
  • 永久性心房顫動

7. 全球心房顫動市場（依治療方法）

  • 藥物治療
  • 電去心房顫動
  • 心導管電氣燒灼術
  • 外科手術

8. 全球心房顫動市場（按技術）

  • 射頻
  • 雷射
  • 冷凍療法
  • 其他技術

9. 全球心房顫動市場（依最終用戶）

  • 醫院
  • 門診手術中心
  • 心導管實驗室
  • 其他最終用戶

第 10 章全球心房顫動市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Abbott Laboratories
  • MicroPort
  • CardiacSense
  • Biosense Webster
  • AtriCure
  • LivaNova
  • Johnson and Johnson
  • ZOLL Medical
  • ACBIO
  • Medtronic
  • Biotronik
  • Philips Healthcare
  • Stereotaxis
  • Boston Scientific
  • Siemens Healthineers
Product Code: SMRC29623

According to Stratistics MRC, the Global Atrial Fibrillation Market is accounted for $17.6 billion in 2025 and is expected to reach $27.3 billion by 2032 growing at a CAGR of 6.5% during the forecast period. Atrial fibrillation is a heart rhythm disorder characterized by rapid and irregular beating of the atria, the upper chambers of the heart. It occurs when electrical signals in the atria become chaotic, disrupting the normal rhythm. This leads to poor blood circulation and increases the risk of stroke, heart failure, and other heart-related complications. Common symptoms include palpitations, fatigue, chest discomfort, and shortness of breath. Early diagnosis and management through medication, lifestyle changes, or surgical intervention are essential for effective treatment.

According to an article published in the National Center for Biotechnology Information in 2021, the prevalence of atrial fibrillation is estimated to be around 37.5 million across the globe and is projected to increase by more than 60.0% by the year 2050.

Market Dynamics:

Driver:

Increasing global prevalence of cardiovascular disorders

The rising incidence of atrial fibrillation (AFib) is linked to aging populations and lifestyle-related risk factors. Obesity, hypertension, and diabetes significantly contribute to the growing burden of cardiovascular diseases. Increased awareness of AFib symptoms prompts early diagnosis and treatment. Sedentary lifestyles and stress-related conditions further elevate the risk of heart disorders. Advancements in diagnostic tools enable better detection of AFib cases. The global demand for effective AFib treatments continues to rise.

Restraint:

Risks and complications associated with AFib treatments

AFib treatments, such as catheter ablation, carry risks of bleeding and infection. Anticoagulant medications increase the likelihood of adverse effects like excessive bleeding. High costs of advanced treatments limit accessibility for many patients. The complexity of procedures requires highly skilled professionals, which can be scarce. Patient non-compliance with long-term medication regimens poses additional challenges. These factors collectively hinder the widespread adoption of AFib therapies.

Opportunity:

Development of minimally invasive treatment options

Minimally invasive procedures like catheter ablation are gaining traction for their reduced recovery times. Innovations in ablation technologies improve precision and patient outcomes. Growing investment in research supports the development of safer treatment methods. Wearable devices for real-time heart monitoring enhance early intervention strategies. Collaborations between medical device companies and healthcare providers drive innovation. These advancements create significant growth opportunities in the AFib market.

Threat:

Intense competition among medical device manufacturers

The AFib treatment market faces fierce competition among leading medical device companies. Rapid technological advancements pressure manufacturers to innovate continuously. Smaller players struggle to compete with established brands offering advanced solutions. Price wars and cost-cutting strategies impact profit margins. Regulatory hurdles for new device approvals slow market entry. Intense competition may lead to market saturation, limiting growth for new entrants.

Covid-19 Impact:

The COVID-19 pandemic disrupted elective AFib procedures due to hospital resource constraints. Telemedicine adoption surged, enabling remote monitoring of AFib patients. Supply chain issues affected the availability of critical medical devices. The pandemic highlighted the importance of early AFib detection in high-risk patients. Post-COVID, increased healthcare spending has accelerated market recovery. Growing awareness of heart health continues to drive demand for AFib treatments.

The paroxysmal atrial fibrillation segment is expected to be the largest during the forecast period

The paroxysmal atrial fibrillation segment is expected to account for the largest market share during the forecast period, due to its high prevalence among diagnosed cases. Its intermittent nature drives demand for early diagnostic and treatment solutions. Advances in wearable monitoring devices aid in the timely detection of paroxysmal AFib. Patient preference for minimally invasive treatments boosts segment growth. Increased healthcare access supports early intervention for paroxysmal cases. The segment benefits from ongoing research into targeted therapies.

The drug therapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the drug therapy segment is predicted to witness the highest growth rate, due to its affordability and widespread availability. Anticoagulants and antiarrhythmic drugs remain critical for managing AFib symptoms. Ongoing research into novel drug formulations enhances treatment efficacy. Patient preference for non-invasive options drives demand for pharmaceutical solutions. Improved access to healthcare in emerging markets supports segment growth. Innovations in personalized medicine further accelerate the adoption of drug therapies.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its large aging population and rising AFib cases. Increasing healthcare expenditure in countries like China and India drives market growth. The region's expanding medical infrastructure supports advanced AFib treatments. Growing awareness of cardiovascular health boosts demand for diagnostic tools. Government initiatives to improve healthcare access enhance market potential. The presence of key medical device manufacturers strengthens the region's dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, due to its advanced healthcare systems. High adoption of innovative AFib treatments like catheter ablation fuels market expansion. The region's strong focus on research and development drives technological advancements. Rising prevalence of lifestyle-related risk factors increases AFib cases. Supportive reimbursement policies enhance patient access to treatments. Strategic partnerships among key players further accelerate market growth.

Key players in the market

Some of the key players in Atrial Fibrillation Market include Abbott Laboratories, MicroPort, CardiacSense, Biosense Webster, AtriCure, LivaNova, Johnson and Johnson, ZOLL Medical, ACBIO, Medtronic, Biotronik, Philips Healthcare, Stereotaxis, Boston Scientific, and Siemens Healthineers.

Key Developments:

In May 2025, Abbott Laboratories introduced the Amplify(TM) Catheter, a next-generation ablation system with enhanced precision for treating paroxysmal atrial fibrillation.

In April 2025, Medtronic launched the PulseSelect(TM) PFA System, a novel pulsed-field ablation technology for safer and faster AFib procedures, reducing patient recovery time.

In March 2025, Boston Scientific announced the POLARx(TM) FIT Cryoablation Balloon, designed for improved adaptability in complex AFib cases, enhancing procedural outcomes.

In February 2025, Philips Healthcare debuted an AI-powered ECG monitoring platform, CardioGuard, for real-time detection of atrial fibrillation in outpatient settings.

Products Covered:

  • Surgical Devices
  • Non-Surgical Devices
  • Pharmacological Drugs

Types Covered:

  • Paroxysmal Atrial Fibrillation
  • Persistent Atrial Fibrillation
  • Permanent Atrial Fibrillation

Treatments Covered:

  • Drug Therapy
  • Cardioversion
  • Catheter Ablation
  • Surgical Procedures

Technologies Covered:

  • Radiofrequency
  • Laser
  • Cryotherapy
  • Other Technologies

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Atrial Fibrillation Market, By Product

  • 5.1 Introduction
  • 5.2 Surgical Devices
  • 5.3 Non-Surgical Devices
  • 5.4 Pharmacological Drugs

6 Global Atrial Fibrillation Market, By Type

  • 6.1 Introduction
  • 6.2 Paroxysmal Atrial Fibrillation
  • 6.3 Persistent Atrial Fibrillation
  • 6.4 Permanent Atrial Fibrillation

7 Global Atrial Fibrillation Market, By Treatment

  • 7.1 Introduction
  • 7.2 Drug Therapy
  • 7.3 Cardioversion
  • 7.4 Catheter Ablation
  • 7.5 Surgical Procedures

8 Global Atrial Fibrillation Market, By Technology

  • 8.1 Introduction
  • 8.2 Radiofrequency
  • 8.3 Laser
  • 8.4 Cryotherapy
  • 8.5 Other Technologies

9 Global Atrial Fibrillation Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Ambulatory Surgical Centers
  • 9.4 Cardiac Catheterization Laboratories
  • 9.5 Other End Users

10 Global Atrial Fibrillation Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 MicroPort
  • 12.3 CardiacSense
  • 12.4 Biosense Webster
  • 12.5 AtriCure
  • 12.6 LivaNova
  • 12.7 Johnson and Johnson
  • 12.8 ZOLL Medical
  • 12.9 ACBIO
  • 12.10 Medtronic
  • 12.11 Biotronik
  • 12.12 Philips Healthcare
  • 12.13 Stereotaxis
  • 12.14 Boston Scientific
  • 12.15 Siemens Healthineers

List of Tables

  • Table 1 Global Atrial Fibrillation Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Atrial Fibrillation Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Atrial Fibrillation Market Outlook, By Surgical Devices (2024-2032) ($MN)
  • Table 4 Global Atrial Fibrillation Market Outlook, By Non-Surgical Devices (2024-2032) ($MN)
  • Table 5 Global Atrial Fibrillation Market Outlook, By Pharmacological Drugs (2024-2032) ($MN)
  • Table 6 Global Atrial Fibrillation Market Outlook, By Type (2024-2032) ($MN)
  • Table 7 Global Atrial Fibrillation Market Outlook, By Paroxysmal Atrial Fibrillation (2024-2032) ($MN)
  • Table 8 Global Atrial Fibrillation Market Outlook, By Persistent Atrial Fibrillation (2024-2032) ($MN)
  • Table 9 Global Atrial Fibrillation Market Outlook, By Permanent Atrial Fibrillation (2024-2032) ($MN)
  • Table 10 Global Atrial Fibrillation Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 11 Global Atrial Fibrillation Market Outlook, By Drug Therapy (2024-2032) ($MN)
  • Table 12 Global Atrial Fibrillation Market Outlook, By Cardioversion (2024-2032) ($MN)
  • Table 13 Global Atrial Fibrillation Market Outlook, By Catheter Ablation (2024-2032) ($MN)
  • Table 14 Global Atrial Fibrillation Market Outlook, By Surgical Procedures (2024-2032) ($MN)
  • Table 15 Global Atrial Fibrillation Market Outlook, By Technology (2024-2032) ($MN)
  • Table 16 Global Atrial Fibrillation Market Outlook, By Radiofrequency (2024-2032) ($MN)
  • Table 17 Global Atrial Fibrillation Market Outlook, By Laser (2024-2032) ($MN)
  • Table 18 Global Atrial Fibrillation Market Outlook, By Cryotherapy (2024-2032) ($MN)
  • Table 19 Global Atrial Fibrillation Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 20 Global Atrial Fibrillation Market Outlook, By End User (2024-2032) ($MN)
  • Table 21 Global Atrial Fibrillation Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 22 Global Atrial Fibrillation Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 23 Global Atrial Fibrillation Market Outlook, By Cardiac Catheterization Laboratories (2024-2032) ($MN)
  • Table 24 Global Atrial Fibrillation Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.